Darren Smith Joins Telix as Deputy Group Chief Financial Officer
Telix is pleased to announce that Darren Smith has joined the Company as Deputy Group Chief Financial Officer.
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
Telix signs a commercial distribution agreement with BIOKOSMOS for prostate cancer investigational imaging product Illuccix® in Greek and Cypriot markets.
Telix Completes A$175 Million Placement and Launches A$25 Million SPP
Telix announces a successful $175 million institutional placement and launches Share Purchase Plan to raise up to $25 million.
Activities Report and Appendix 4C for December 2021 Quarter
Telix provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2021.
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
Telix announces agreement with NUCLIBER S.A. for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in Spain.
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
The Brazilian Health Regulatory Agency has granted an exceptional authorisation for Illuccix® (TLX591-CDx), Telix’s lead prostate cancer imaging product.
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
Australian Therapeutic Goods Administration has approved Illuccix® for the diagnostic imaging of men with prostate cancer.
Activities Report and Appendix 4C for September 2021 Quarter
Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix Establishes Commercial Hub in Geneva, Switzerland
Telix is pleased to announce that it has established a new commercial hub in Geneva through its subsidiary, Telix Pharmaceuticals (Switzerland) GmbH.